Search Results
Your search for The A,The A matches 32372 pages
Showing 12051 - 12100Surgeon General’s Report on Smoking Cessation Highlights Evidence-Based Ways to Help People Quit
ASCO applauds the Office of the Surgeon General for releasing its first report on smoking cessation in 30 years. The report provides the latest evidence-based information on the public health consequences of tobacco use and effective ways to help people quit smoking. Smoking rates in the United...
Survey Says: A Low-Tech Approach Leads to High-Quality Care in South Africa
An American medical student travels to rural Uganda; there, he finds most villagers walking miles to receive health care at the nearby district hospital. Upon arrival, they spend hours waiting in line. Some patients make this trip monthly. Before entering internal medicine residency, Daniel O’Neil, ...
ASCO, Project ECHO Partner to Pilot Impactful Cancer Tele-Education Program in Nepal
Cancer care for patients in rural areas is challenging—for example, in the United States, only 3% of medical oncologists practice in rural areas, and patients must travel long distances to see specialists. Patients may also have trouble managing complications from care or follow-up from treatment....
The Parker Institute for Cancer Immunotherapy Awards $2.75 Million to Support Six Early-Career Researchers
The parker institute for cancer immunotherapy (PICI) recently announced awards for six early-career researchers through the Parker Scholars, Parker Bridge Fellows, and Parker Senior Fellows programs. They are receiving a total of up to $2.75 million in funding to advance their research in profound...
Don’t Expect Transgender Patients to ‘Out’ Themselves
Although more transgender patients are presenting to breast centers for imaging, many “report significant social stigma when seeking care,” according to a study in the Journal of Breast Imaging.1 Reported verbal abuse and other forms of harassment “can lead to transgender patients concealing their...
Addressing the Needs of Transgender Patients for Breast Cancer Screening in Comfortable and Inclusive Environments
An analysis of breast imaging center websites and a literature search for research articles on transgender breast health found that “issues related to transgender breast imaging are not well addressed in the radiology literature or in the radiology community, even though more transgender patients...
AML Pioneer and Giant, Clara D. Bloomfield, MD, FASCO, Dies at 77
Physicians and scientists interested in acute myeloid leukemia (AML) have lost one of the community’s shining lights with the death of Clara D. Bloomfield, MD, FASCO, on March 1, 2020, at age 77 years. Dr. Bloomfield is well known for her more than 50 years of groundbreaking research in blood...
I Wasn’t Prepared for the Emotional Turmoil of Breast Cancer
Nearly a decade ago, my mother tested positive for the BRCA1 mutation; soon after, my twin sister and I were tested for the inherited defective gene, and I learned I, too, have the BRCA1 mutation. My sister is not a carrier of the mutation. Although there is a long history of both breast and...
The Opioid Crisis as Told From the Streets to the Clinics and Its Unintended Consequences
The history of drug addictions and epidemics in the United States dates back to the Civil War, when morphine was introduced as a pain medication for wounded soldiers. Regular off-label use of morphine quickly spread from war hospitals to the general public. It is estimated that more than 400,000...
A Cello for Michayla
The ASCO Post is pleased to reproduce installments of Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays, historical...
Selected ASH Abstracts on Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
ABSTRACT 355: MURANO study: Four-year analysis confirms sustained benefit (compared to bendamustine and rituximab; n = 195) of time-limited venetoclax/rituximab (n = 194) in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; ClinicalTrials.gov NCT02005471)1...
Selected ASH Abstracts on Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
To complement The ASCO Post’s continued comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapies for newly diagnosed chronic lymphocytic leukemia (CLL) and...
Expert Point of View: John M. Carethers, MD
The analysis of the National Cancer Database is one of a number of studies describing sociodemographic-related disparities in colorectal cancer outcomes, according to session Co-Chair John M. Carethers, MD, Professor and Chair of the Department of Internal Medicine at the University of Michigan,...
Studies Aim to Understand Young-Onset Colorectal Cancer
The incidence of colorectal cancer among adults younger than age 50 has risen more than 50% over the past 25 years. Researchers are attempting to understand this phenomenon, as described in several studies presented at the 2020 Gastrointestinal Cancers Symposium that offered new insights....
Veterans Health Bill Promotes Comprehensive Prostate Cancer Care Program
The American Urological Association (AUA) announced its support for the Veterans Prostate Cancer Treatment and Research Act, introduced on March 5 by Rep. Neal Dunn, MD (R-FL-3), and Rep. Joe Cunningham (D-SC-1). This bill supports the development and implementation of a Veterans Health...
Randall A. Oyer, MD, Named President of the Association of Community Cancer Centers
At the Association of Community Cancer Centers (ACCC) 46th Annual Meeting & Cancer Center Business Summit, held March 4–6 in Washington, DC, Randall A. Oyer, MD, was named ACCC President for 2020–2021. Dr. Oyer announced that the theme of his presidency will be “Community Oncology Can Close the ...
Charles Sawyers, MD, Receives Knudson Award in Cancer Genetics
The National Cancer Institute (NCI) has named Charles Sawyers, MD, as the recipient of the 2020 Alfred G. Knudson Award in Cancer Genetics. Dr. Sawyers is Chair of the Human Oncology and Pathogenesis Program and the Marie-Josée and Henry R. Kravis Chair at Memorial Sloan Kettering Cancer Center, as ...
Memorial Sloan Kettering Announces Two New Appointments
Memorial Sloan Kettering Cancer Center (MSK) recently appointed Sergio Giralt, MD, and Miguel-Angel Perales, MD, as Deputy Division Head of the Division of Hematologic Malignancies and Chief of the Adult Bone Marrow Transplant Service, respectively. Dr. Giralt: New Roles and Old Former Chief of...
Actively Recruiting Clinical Trials on Colorectal Cancer
This Clinical Trials Resource Guide lists actively recruiting trials on colorectal cancer, focusing on novel treatments, combinations of treatments, and testing options to determine which patients may be most likely to benefit from further treatment. More information on these trials is available on ...
Adding Radiotherapy to Immunotherapy in Renal Cell Carcinoma: Studies Find Mixed Results
Despite recent enthusiasm for combining stereotactic body radiation therapy with immunotherapy in renal cell carcinoma, two preliminary studies presented at the 2020 Genitourinary Cancers Symposium suggest that it may not be the best path forward. In one study, the combination of nivolumab plus...
Neratinib Combined With Capecitabine in Previously Treated Advanced HER2-Positive Breast Cancer
On February 25, 2020, neratinib (Nerlynx) was approved for use in combination with capecitabine for treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti–HER2-based regimens in the metastatic setting.1,2 Supporting Efficacy ...
Expert Point of View: Tanguy Y. Seiwert, MD
Tanguy Y. Seiwert, MD, moderator of the session on the phase II trial of neoadjuvant nivolumab with or without ipilimumab in patients with oral cavity cancer, underscored concerns about differences in outcome measures. Dr. Seiwert is Director of the Head and Neck Cancer Oncology Disease Group and...
Phase II Trial Finds Neoadjuvant Immunotherapy Feasible in Oral Cavity Cancer
The results of a phase II study suggest that a short course of immunotherapy prior to surgery for oral cavity cancer may trigger tumor regression, possibly providing long-term benefits for patients. According to data presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium,1 a 3-week ...
Immune-Restorative Agent May Boost Immunotherapy Response in Advanced Head and Neck Cancer
Immune modulation with checkpoint inhibitors has shown beneficial effects in advanced head and neck squamous cell carcinoma, but responses have been limited to a small number of patients. According to data presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium, however, an...
Cancer During Pregnancy: Whose Moral Compass to Follow?
As has often been written, “Cancer is the greatest equalizer.” It tends to strike its victims regardless of their financial status. In low- and middle-income countries, however, the impact of poverty on the treatment of cancer is strikingly conspicuous. It is the major catalyst for delay in seeking ...
How Exercise Oncology Can Improve Cancer Outcome and Survivorship
Researchers from the American College of Sports Medicine (ACSM) recently reviewed hundreds of epidemiologic studies on the link between physical activity and both cancer risk and cancer mortality. A subsequent analysis of the findings by a panel of experts representing 17 partner organizations,...
Expert Point of View: Philip J. Saylor, MD
Philip J. Saylor, MD, Attending Physician at Massachusetts General Hospital and Assistant Professor at Harvard Medical School, Boston, commented on this study. “The results that were presented are clearly exciting and cause us to look forward to a likely phase III study of this strategy. The high...
Early Data Show Activity for Enfortumab Vedotin Plus Pembrolizumab in Advanced Bladder Cancer
It may be possible to use a platinum-free combination as first-line treatment for advanced or metastatic urothelial carcinoma in cisplatin-ineligible patients, if results of the phase Ib/II EV-103 trial hold up. The combination of the newly approved antibody-drug conjugate (enfortumab vedotin) and...
Oncologists on the Front Lines of COVID‑19
Coronavirus disease 2019 (COVID-19) is dramatically affecting health-care systems. This is the first in a series of interviews The ASCO Post will conduct with oncologists, to learn what they and their cancer centers are doing to deal with the crisis. In this article, we talk with John Cole, MD, a...
Clinical and Dermoscopic Features of Uncommon Melanoma Variants: Systematic Review
In a literature review published by Pampena et al in JAMA Dermatology, researchers provided detailed and extensive information about the features of several different kinds of rare cutaneous melanomas. According to the researchers, the analysis was performed to “…provide a comprehensive overview of ...
Patients With Certain Cancers May Be at a Higher Risk for Atrial Fibrillation
People with a history of cancer have an over twofold risk of developing atrial fibrillation, the most common heart rhythm disorder, compared to the general population, according to research presented at the American College of Cardiology’s Annual Scientific Session (Abstract 1216-235). In...
Lenvatinib/Pembrolizumab in Previously Treated Patients With Advanced Endometrial Cancer
As reported in the Journal of Clinical Oncology by Vicky Makker, MD, and colleagues, findings from a phase Ib/II trial indicate that the combination of lenvatinib and pembrolizumab is active in patients with previously treated advanced endometrial carcinoma. Study Details The report is the primary ...
Nivolumab for Children and Young Adults With Relapsed or Refractory Solid Tumors or Lymphoma
In the phase I/II ADVL1412 study reported in The Lancet Oncology, Davis et al identified the phase II dosage of nivolumab monotherapy in children and young adults with relapsed or refractory solid tumors or lymphoma. Objective responses were observed in patients with lymphoma, but not in those with ...
A Message From the FDA OCE for Patients With Cancer and Health-Care Providers on COVID-19
On March 23, the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) issued the following statement: The FDA OCE recognizes that patients with cancer constitute a vulnerable population at risk of contracting the coronavirus disease (COVID-19). While everyone’s daily lives...
Phase III JAVELIN Gastric 100 Trial Finds No Survival Benefit for Maintenance Avelumab
In the phase III JAVELIN Gastric 100 trial, a strategy called “switch maintenance” with the immune checkpoint inhibitor avelumab after 12 weeks of first-line induction chemotherapy did not statistically improve overall survival for treatment-naive patients with HER2-negative advanced gastric or...
Expert Point of View: Daniel V.T. Catenacci, MD
The analysis by Chao et al “highlights how well patients with MSI-H tumors do, compared to microsatellite-stable patients, and how much better they do in a randomized setting, being exposed to immunotherapy as compared to standard-of-care chemotherapy…The data also show that this is a...
Pembrolizumab in MSI-H and CPS ≥ 10 Advanced Gastric or Gastroesophageal Junction Cancer: Subanalysis of KEYNOTE-059, -061, and -062
The survival benefit of pembrolizumab in advanced gastric/gastroesophageal junction cancer with microsatellite instability–high (MSI-H) tumors or a combined positive score (CPS) ≥ 10 was established in post hoc subanalysis of three KEYNOTE trials. Findings were presented at the 2020...
Expert Point of View: Richard L. Schilsky, MD, FACP, FSCT, FASCO
Richard L. Schilsky, MD, FACP, FSCT, FASCO, Chief Medical Officer and Executive Vice President of ASCO, called the 74% response rate to cisplatin/gemcitabine “remarkable.” “What’s impressive to me is the high response rate, as well as the progression-free and overall survival data—these data are...
Cisplatin/Gemcitabine Alone and With Veliparib in BRCA-Mutated Advanced Pancreatic Cancer
In patients with pancreatic ductal adenocarcinoma and a germline BRCA/PALB2 mutation, first-line therapy with cisplatin plus gemcitabine yielded high response rates and encouraging survival, according to Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, who presented the findings...
Genetic Counseling and Testing of Patients With Pancreatic Cancer
Routine genetic counseling and multigene testing of patients with pancreatic cancer result in the detection of mutations that are actionable, not only for patients, but also for at-risk family members. At the Dana-Farber Cancer Institute in Boston, the use of a systemized, automated referral system ...
Maintenance Olaparib in BRCA1/2-Positive Pancreatic Cancer Yields Improved Progression-Free Survival, Preserves Quality of Life
Health-related quality of life was preserved during maintenance olaparib in patients with BRCA 1/2-positive pancreatic cancer, as evidenced by a low symptom burden over time.1 POLO investigators reported their findings in posters presented at the 2020 Gastrointestinal Cancers Symposium. Other...
Expert Point of View: Christopher M. Booth, MD
Christopher M. Booth, MD, the invited discussant of the BEACON CRC quality-of-life findings, applauded the investigators for choosing overall survival and quality of life as endpoints in a trial that benefits a “vulnerable patient population with unmet needs.” Patients with BRAF-mutated metastatic...
Mature Follow-up of BEACON CRC Study Reports Quality-of-Life Measures and Survival Outcomes
For patients with previously treated metastatic colorectal cancer harboring BRAF V600E mutations, the phase III BEACON CRC study showed the benefit for combining two or three targeted agents vs the standard of care.1 With further follow-up, the study has now also shown a benefit for the triplet and ...
TAPUR Basket Study: Biomarker-Driven Treatment Strategies Yield Benefits in Colorectal Cancer
Positive findings on the potential benefit of molecularly targeted drugs in patients with advanced colorectal cancer were presented at the 2020 Gastrointestinal Cancers Symposium, validating the purpose of ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) study.1-3 TAPUR, the first...
Expert Point of View: A. Craig Lockhart, MD
A. Craig Lockhart, MD, Professor of Medicine, University of Miami Sylvester Comprehensive Cancer Center, applauded the study for making patient-reported outcomes a prespecified endpoint and described the value of having this information. Dr. Lockhart was the invited discussant. “The U.S. Food and...
IMbrave150 Prespecified Analysis Adds Improved Quality-of-Life to Survival Benefits Reaped With Atezolizumab Plus Bevacizumab
New findings from a prespecified analysis of the pivotal IMbrave150 trial revealed improved quality of life for patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab in the first-line setting. These results were reported by Peter R. Galle, MD, at the 2020...
Conference Highlights From the 2020 Gastrointestinal Cancers Symposium
This past January, the 2020 Gastrointestinal Cancers Symposium was held in San Francisco. More than 3,600 individuals attended and more than 900 abstracts and posters were presented. Among the highlights presented at the meeting and reported in the pages of The ASCO Post, several studies in...
A Discussion About CAR T-Cell Therapy for Multiple Myeloma and Lymphoma
Dr. Armitage discusses the role of CAR T-cell therapy in the management of multiple myeloma and lymphoma in a conversation with his colleagues Dr. Holstein and Dr. Lunning.
A Case of Diffuse Large B-Cell Lymphoma
Dr. Armitage presents a case and asks Dr. Lunning to describe how he would treat this patient. The patient is a 52-year-old man who found a neck mass himself. He went to his doctor and was prescribed antibiotics. When the antibiotics failed to impact the mass, a biopsy was performed and a diagnosis ...
A Case of Relapsed/Refractory Multiple Myeloma
Dr. Armitage presents a case and asks Dr. Holstein to comment about her approach to treatment. The patient is be a 59-year-old man who had presented with symptomatic myeloma with bone pain and he was feeling unwell. He had bone lesions on images. He was anemic. This all happened 2 years ago. He was ...
